Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Shareholders for Bristol-Myers Squibb Company, held on May 5, 2026. The filing details the voting outcomes for director elections, executive compensation, equity plans, auditor ratification, and a shareholder proposal.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
The following matters were voted upon by shareholders:
- Director Elections: All 11 nominees were elected to serve until the 2027 Annual Meeting. Vote counts ranged from approximately 1.46 billion to 1.53 billion "For" votes.
- Executive Compensation: The advisory vote to approve named executive officer compensation was approved with approximately 1.46 billion "For" votes against 72.5 million "Against" votes.
- Stock Award Plan: The 2026 stock award and incentive plan was approved with approximately 1.47 billion "For" votes.
- Auditor Ratification: The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 was ratified with approximately 1.71 billion "For" votes.
- Shareholder Proposal: A proposal requiring the board chairperson to be an independent director was not approved. It received approximately 422 million "For" votes versus 1.11 billion "Against" votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting results.
Key Facts for Investor Verification
- Verify the re-election of all 11 board nominees, noting the specific "Against" vote percentages for each director.
- Confirm the rejection of the shareholder proposal regarding an independent board chair, which received significant opposition (approx. 72% against).
- Note the ratification of Deloitte & Touche LLP as the auditor for the 2026 fiscal year.
- Review the approval of the 2026 stock award and incentive plan for potential dilution impacts.